Genstar GNT(formerly UroGen)-- an interesting speculation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genstar GNT(formerly UroGen)-- an interesting speculation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who started this subject	12/17/2001 7:39:55 AM
From: Paul Lee	of 100

GenStar's Cancer Product Suppresses the Growth of Prostate Tumors and Enhances the Effects of Radiation Therapy BUSINESS WIRE - December 17, 2001 07:31 SAN DIEGO, Dec 17, 2001 (BW HealthWire) -- GenStar Therapeutics (AMEX:GNT) today announced pre-clinical data describing the efficacy of its prostate cancer product, the DUAL-AD vector system. In these studies, GenStar's DUAL-AD vector system was shown to eradicate tumors through a combination of direct tumor destruction, radiation enhancement and the generation of anti-tumor immunity. This data was presented at the 10th International Conference of Cancer Gene Therapy in San Diego, CA. "Our novel approach has the benefit of multiple therapeutic activities and is designed to enhance the effects of radiation therapy. In addition to treating prostate cancer, the technology may be broadly applied to increase the efficacy of radiation in the wide variety of tumors treated by radiotherapy " stated Robert E. Sobol, M.D. Chief Executive Officer. "The results of the presented studies will be employed in regulatory filings to support the initiation of a prostate cancer clinical trial in the coming year." GenStar's DUAL-AD cancer product is comprised of a mixture of two adenoviral vectors that complement each other to directly destroy tumor tissues and to express the gene for interleukin-3 (IL-3) that enhances the effects of radiation and induces anti-tumor immune responses. GenStar's DUAL-AD IL-3 vector system will be initially developed for the treatment of prostate cancer. GenStar is also developing a Pan-Cancer DUAL-AD product that functions in all tumors and permits broad application of the technology to enhance the efficacy of radiation in the large number of cancers that are treated by radiotherapy. The total potential market for this Pan-Cancer product is significant, as over 600,000 patients are treated with radiation therapy annually in the United States. GenStar's radiation-enhancing IL-3 gene therapy technology is covered by an issued U.S. patent.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next